Innate Pharma

(OTC) IPHYF

Current Price$1.65

Market Cap$154.94M

Since IPO (2013)-51%

5 Year-57%

1 Year+14%

1 Month+10%

Innate Pharma Financials at a Glance

Market Cap

$154.94M

Revenue (TTM)

€18.60M

Net Income (TTM)

-€98.64M

EPS (TTM)

-$0.61

P/E Ratio

-2.68

Dividend

$0.00

Beta (Volatility)

-0.02 (Low)

Dividend

$0.00

Beta (Volatility)

-0.02 (Low)

Price

$1.65

Volume

6,700

Open

$1.65

Price

$1.65

Volume

6,700

Open

$1.65

Previous Close

$1.65

Daily Range

$1.65 - $1.65

52-Week Range

$1.31 - $2.25

Estimated Earnings Date

Sep 17, 2026

Dividend

$0.00

Beta (Volatility)

-0.02 (Low)

Price

$1.65

Volume

6,700

Open

$1.65

Previous Close

$1.65

Daily Range

$1.65 - $1.65

52-Week Range

$1.31 - $2.25

Estimated Earnings Date

Sep 17, 2026

IPHYF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innate Pharma

Industry

Biotechnology

Sector

Health Care

Employees

163

CEO

Jonathan Dickinson, MBA

Website

www.innate-pharma.com

Headquarters

Marseille, 13009, FR

IPHYF Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-21%

Net Income Margin

-18%

Return on Equity

-271%

Return on Capital

-2%

Return on Assets

-78%

Earnings Yield

-37.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$154.94M

Shares Outstanding

93.90M

Volume

6.70K

Avg. Volume

125

Financials (TTM)

Gross Profit

€2.79M

Operating Income

-€53.43M

EBITDA

-€43.65M

Operating Cash Flow

-€52.74M

Capital Expenditure

-€139.95K

Free Cash Flow

-€52.88M

Cash & ST Invst.

€34.30M

Total Debt

€22.56M

Innate Pharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

€1.12M

-94.8%

Gross Profit

€438.84K

+114.0%

Gross Margin

39.34%

N/A

Market Cap

$154.94M

N/A

Market Cap/Employee

$856.02K

N/A

Employees

181

N/A

Net Income

-€27.82M

-199.6%

EBITDA

-€18.59M

-78.8%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

€34.30M

-62.9%

Total Debt

€22.56M

-43.4%

Accounts Receivable

€12.40M

-73.3%

Inventory

€0.00

N/A

Long Term Debt

€13.77M

-55.5%

Short Term Debt

€8.80M

-1.5%

Return on Assets

-78.41%

N/A

Return on Invested Capital

-2.20%

N/A

Free Cash Flow

-€21.66M

-2.5%

Operating Cash Flow

-€21.58M

-2.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MLLCFMolecular Partners AG

MLLCFMolecular Partners AG$4.85+0.00%

AAWHAscend Wellness Holdings, Inc.

AAWHAscend Wellness Holdings, Inc.$0.54+1.92%

JWCTFJW (Cayman) Therapeutics Co. Ltd

JWCTFJW (Cayman) Therapeutics Co. Ltd$0.24+0.00%

NDTPNDT Pharmaceuticals Inc.

NDTPNDT Pharmaceuticals Inc.$0.56+6.90%

SCNLFScancell Holdings plc

SCNLFScancell Holdings plc$0.25+0.00%

BXPHFBotanix Pharmaceuticals Limited

BXPHFBotanix Pharmaceuticals Limited$0.02+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98+0.02%

NOKNokia

NOKNokia$14.80+0.05%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.59+0.04%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.46-0.05%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.04-0.02%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.02-0.00%

ONDSOndas

ONDSOndas$9.33-0.05%

Questions About IPHYF

What is the current price of Innate Pharma?

Innate Pharma is trading at $1.65 per share.

What is the 52-week range for Innate Pharma?

Over the past 52 weeks, Innate Pharma has traded between $1.31 and $2.25.

How much debt does Innate Pharma have?

As of the most recent reporting period, Innate Pharma reported total debt of €26.51M.

How much cash does Innate Pharma have on hand?

Innate Pharma reported €32.99M in cash and cash equivalents in its most recent financial results.

What is Innate Pharma’s dividend yield?

Innate Pharma does not currently have a dividend yield.

Innate Pharma

Innate Pharma Financials at a Glance

IPHYF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Innate Pharma

IPHYF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Innate Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IPHYF

What is the current price of Innate Pharma?

What is the 52-week range for Innate Pharma?

How much debt does Innate Pharma have?

How much cash does Innate Pharma have on hand?

What is Innate Pharma’s dividend yield?

Premium Investing Services